Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
132
datasets available to search
ShareScore release 0.9.0
Dataset results
132 results for “nasal polyps”
Increased Autoreactivity and Maturity in EBI2+ Antibody-Secreting Cells from Nasal Polyps
GEO Series GSE270953. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Other.
Transcriptome analysis identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in nasal polyp epithelial cells of patients suffering from Nonsteroidal anti-inflammatory drugs- Exacerbated
GEO Series GSE158277. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Expression data from CRS with nasal polyps (CRSwNP) and normal control
GEO Series GSE194282. Homo sapiens. 14 samples. Type: Expression profiling by array.
Exon Array Analysis of Asthmatic Chronic Rhinosinusitis with Nasal Polyps
GEO Series GSE23552. Homo sapiens. 39 samples. Type: Expression profiling by array.
Transcriptome profiling of nasal polyp derived human IL17RB positive and negative T-helper cells
GEO Series GSE70898. Homo sapiens. 12 samples. Type: Expression profiling by array.
miRNA repertoires of ex-vivo bronchial, nasal, and polyps cells cultured from healthy and CF donors
GEO Series GSE159708. Homo sapiens. 24 samples. Type: Non-coding RNA profiling by high throughput sequencing.
The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps
ClinicalTrials.gov study NCT06015243. IPD Sharing: NO. Countries: 0. Publications: 0.
A Study of Different Endoscopic Surgery Procedures in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
ClinicalTrials.gov study NCT03878355. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Mast cell heterogeneity in human nasal polyps
GEO Series GSE279289. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Neutrophilic inflammation and epithelial barrier disruption in nasal polyps characterize NSAID-exacerbated respiratory disease
GEO Series GSE189690. Homo sapiens. 26 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab "
<p>This record contains raw data related to article “Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab"</p> <p>Abstract</p> <p><strong>Background and objective: </strong> Background: Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, has been recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, demonstrating a rapid onset of clinical effects. CRSwNP is characterized by an extended type-2 inflammatory involvement that can be assessed by extended nitric oxide analysis. Objective: In this study we investigated whether Dupilumab is associated with a rapid improvement in extended nitric oxide parameters, lung function and clinical outcomes in patients with CRSwNP.</p> <p><strong>Methods: </strong> : Consecutive patients with CRSwNP and indication to be treated with Dupilumab were evaluated for extended nitric oxide analysis (exhaled, FENO; bronchial, JawNO and alveolar, CalvNO components; nasal, nNO) and lung function 15 and 30 days after treatment initiation, and for clinical outcomes (nasal polyps score, NPS; quality of life questionnaires; visual analogue scales, VAS, for main symptoms, asthma control test, ACT) after 30 days of treatment initiation.</p> <p><strong>Results: </strong> 33 patients were enrolled. All extended nitric oxide and lung function parameters significantly improved after 15 days of treatment remaining stable at 30 days. NPS, VAS for main CRSwNP symptoms, quality of life questionnaires and ACT significantly improved after 30 days of treatment initiation.</p> <p><strong>Conclusion: </strong> Dupilumab is associated with very rapid improvement in type 2 inflammation in all airway districts and this is associated with improved lung function and clinical parameters in patients with CRSwNP.</p>
Dataset related to article "Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps "
<p>This record contains raw data related to article “Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps"</p> <p>Abstract</p> <p>To date, no disease-specific tool has been available to assess the impact of chronic rhinosinusitis with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). Therefore, the purpose of this study was to develop and validate a questionnaire specifically designed to this aim: the Nasal Polyposis Quality of Life (NPQ) questionnaire. As indicated in the current guidelines, the development and validation of the NPQ occurred in two separate steps involving different groups of patients. The questionnaire was validated by assessing internal structure, consistency, and validity. Responsiveness and sensitivity to changes were also evaluated. In the development process of NPQ an initial list of 40 items was given to 60 patients with CRSwNP; the 27 most significant items were selected and converted into questions. The validation procedure involved 107 patients (mean age 52.9 ± 12.4). NPQ revealed a five-dimensional structure and high levels of internal consistency (Cronbach's alpha 0.95). Convergent validity (Spearman' coefficient r = 0.75; <em>p</em> < 0.01), discriminant validity (sensitivity to VAS score), and reliability in a sample of patients with a stable health status (Interclass Coefficient 0.882) were satisfactory. Responsiveness to clinical changes was accomplished. The minimal important difference was 7. NPQ is the first questionnaire for the assessment of HRQoL in CRSwNP. Our results demonstrate that the new tool is valid, reliable, and sensitive to individual changes.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.